Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02, Zacks reports.
Oncolytics Biotech Price Performance
Shares of NASDAQ ONCY traded down $0.05 during mid-day trading on Thursday, hitting $1.09. The company had a trading volume of 403,903 shares, compared to its average volume of 1,003,741. Oncolytics Biotech has a 12 month low of $0.33 and a 12 month high of $1.51. The firm has a market cap of $108.89 million, a P/E ratio of -4.02 and a beta of 1.32. The business’s 50-day simple moving average is $1.22 and its 200-day simple moving average is $0.94.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on ONCY shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Wednesday, October 8th. Lake Street Capital began coverage on Oncolytics Biotech in a research note on Wednesday, August 13th. They issued a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen raised Oncolytics Biotech from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Zacks Research upgraded Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Oncolytics Biotech has a consensus rating of “Moderate Buy” and an average target price of $5.00.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
- Five stocks we like better than Oncolytics Biotech
- What is Put Option Volume?
- Forget Netflix—Paramount Skydance’s $3B Plan Is Turning Heads on Wall Street
- ETF Screener: Uses and Step-by-Step Guide
- AMD to $300 Looks Easy—Here’s Why $500 Could Be Next
- Utilities Stocks Explained – How and Why to Invest in Utilities
- $5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
